NCT00838253View on ClinicalTrials.gov

Safety and Efficacy Study of Istaroxime in Acute Decompensated Heart Failure Patients

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2009

Conditions
Heart Failure
Interventions
DRUG

Istaroxime

Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours

DRUG

Istaroxime

Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours

DRUG

Istaroxime

Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours

DRUG

Placebo

Placebo continuous i.v. infusion for 24 hours

Sponsors
All Listed Sponsors
lead

Debiopharm International SA

INDUSTRY